enGene (NASDAQ:ENGN) Issues Earnings Results, Misses Expectations By $0.18 EPS

enGene (NASDAQ:ENGN) posted its earnings results on Monday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18), Zacks reports.

enGene Price Performance

NASDAQ ENGN opened at $9.22 on Wednesday. The company has a market cap of $595.43 million, a price-to-earnings ratio of -4.03 and a beta of -0.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The stock’s fifty day moving average price is $7.90 and its 200 day moving average price is $5.83. enGene has a 1 year low of $2.65 and a 1 year high of $11.14.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. Citizens Jmp lifted their price target on shares of enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of enGene in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of enGene in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.38.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC raised its stake in shares of enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock worth $399,000 after purchasing an additional 35,327 shares during the last quarter. Millennium Management LLC increased its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the period. Paloma Partners Management Co purchased a new position in enGene during the 2nd quarter worth approximately $38,000. Raymond James Financial Inc. lifted its stake in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the period. Finally, Cresset Asset Management LLC acquired a new stake in enGene during the 2nd quarter valued at approximately $36,000. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.